Oncology News and Research RSS Feed - Oncology News and Research Twitter

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.
Increasing radiotherapy can significantly improve survival for children with intracranial ependymoma

Increasing radiotherapy can significantly improve survival for children with intracranial ependymoma

Two studies to be presented today (Sunday) at the 3rd ESTRO Forum in Barcelona, Spain, show that increasing the dose of radiotherapy given to children with an intracranial ependymoma, a form of cancer of the central nervous system, can significantly improve their survival. [More]
Brachytherapy improves overall survival for women with inoperable early stage endometrial cancer

Brachytherapy improves overall survival for women with inoperable early stage endometrial cancer

Women who have early stage endometrial cancer and are inoperable tend to live longer if they have been treated with brachytherapy with or without external beam radiation, according to new research to be presented at the 3rd ESTRO Forum in Barcelona, Spain, on Sunday. [More]
Mediclinic Middle East plans to construct new general hospital in Dubai

Mediclinic Middle East plans to construct new general hospital in Dubai

Mediclinic Middle East today announces plans to construct a new general hospital, similar in scope to its existing Mediclinic City Hospital, in a strategic location on Umm Suqeim Road between the junctions of Al Khail Road and Sheikh Mohammed Bin Zayed Road. [More]
Combination treatment effective for HCV genotype-1 mono-infected patients

Combination treatment effective for HCV genotype-1 mono-infected patients

Results presented today at The International Liver Congress 2015 show that the sofosbuvir (SOF)/daclatasvir (DCV) treatment combination is effective amongst hepatitis C virus (HCV) genotype-1 mono-infected patients. These results are significant because whilst other combinations have been widely reported on, there have been few data until now regarding the use of SOF/DCV combination in real world situations. [More]
New computational model helps study how emerging metastatic tumors interact with immune system

New computational model helps study how emerging metastatic tumors interact with immune system

You think that your immune system is there to protect you. But what happens when it starts working against you? In the earliest stages of cancer formation, the immune system is forced to make a momentous decision. It either activates and suppresses tumor growth to help the body fight disease, or it becomes dysfunctional, helping the tumor grow and making treatment more difficult. Because this tipping point occurs before a person even realizes something is wrong, doctors are unable to directly observe this critical stage. [More]
Elekta introduces new Leksell Gamma Knife Icon to treat patients with brain disease

Elekta introduces new Leksell Gamma Knife Icon to treat patients with brain disease

With the introduction of Elekta's new Leksell Gamma Knife Icon, the benefits of precision cranial radiosurgery are now available for more patients with a wider variety of tumor types and sizes. [More]
iCAD announces adoption of Xoft Axxent Electronic Brachytherapy System in Spain

iCAD announces adoption of Xoft Axxent Electronic Brachytherapy System in Spain

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced the first Xoft Axxent Electronic Brachytherapy (eBx) System in Spain is now available at the Hospital Miguel Servet for the treatment of early-stage breast cancer, non-melanoma skin cancer and gynecological cancers. [More]
Study explores innovative approach to identifying successful treatment for HER2+ breast cancer

Study explores innovative approach to identifying successful treatment for HER2+ breast cancer

Ahmad M. Khalil, PhD, knew the odds were against him -- as in thousands upon thousands to one. Yet he and his team never wavered from their quest to identify the parts of the body responsible for revving up one of the most aggressive forms of breast cancer, HER2+. This month in Breast Cancer Research and Treatment, Khalil and his colleagues at Case Western Reserve University proved the power of persistence; from a pool of more than 30,000 possibilities, they found 38 genes and molecules that most likely trigger HER2+ cancer cells to spread. [More]
Research highlights value of serological testing for Coeliac disease in anyone with symptoms

Research highlights value of serological testing for Coeliac disease in anyone with symptoms

Coeliac disease is one of the most common life-long conditions in Europe, yet many people remain undiagnosed and lengthy diagnostic delays may be putting lives at risk. Today, doctors are being urged to consider testing for Coeliac disease in anyone showing signs and symptoms of the condition and to consider screening everyone in high-risk groups. [More]
Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for RELISTOR (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. [More]
Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. [More]
Oncologists publish review of advanced clinical treatments for pancreatic cancer

Oncologists publish review of advanced clinical treatments for pancreatic cancer

The oncologists Manuel Hidalgo, Director of the Clinical Research Programme of the Spanish National Cancer Research Centre, and Ignacio Garrido-Laguna, member of the Experimental Therapeutics Program at Huntsman Cancer Institute of the University of Utah (USA), have recently published a review of state-of-the-art clinical treatments for pancreatic cancer -- including the most current therapies and innovative research -- in the prestigious scientific journal Nature Reviews Clinical Oncology. [More]
Penn researchers find molecular bond between DNA damage, cellular senescence and premature aging

Penn researchers find molecular bond between DNA damage, cellular senescence and premature aging

Like a beloved pair of jeans, human DNA accumulates damage over time, and older people's bodies can't repair it as well. Many scientists believe a build up of damage can cause cells to enter an irreversible dormant state known as senescence. Cellular senescence is believed to be responsible for some of the telltale signs of aging, such as weakened bones, less resilient skin and slow-downs in organ function. [More]
ViewRay to exhibit MRI-guided radiation therapy system at ESTRO Forum

ViewRay to exhibit MRI-guided radiation therapy system at ESTRO Forum

ViewRay, makers of the world's first and only MRI-guided radiation therapy system, announced today that the company will showcase its MRIdian System at the 3rd ESTRO Forum, the annual meeting of the European Society for Radiotherapy and Oncology, being held April 24-28, 2015 in Barcelona, Spain. [More]
Accuray to highlight CyberKnife, TomoTherapy technologies at ESTRO meeting

Accuray to highlight CyberKnife, TomoTherapy technologies at ESTRO meeting

Accuray Incorporated announced today that the company will highlight new CyberKnife and TomoTherapy technologies at the European Society for Therapeutic Radiology and Oncology meeting, booth #2100, in Barcelona, Spain, April 24 – 27, 2015. [More]
Mylan introduces generic Sofosbuvir 400 mg tablets in India under brand name MyHep

Mylan introduces generic Sofosbuvir 400 mg tablets in India under brand name MyHep

Mylan N.V. today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched generic Sofosbuvir 400 mg tablets under the brand name MyHep in India. [More]
ADCs based on alpha-amanatin may help treat colorectal cancer

ADCs based on alpha-amanatin may help treat colorectal cancer

For some time, cancer scientists have considered the toxin, alpha-amanatin derived from "death cap" mushrooms, as a possible cancer treatment. However, due to its penchant for causing liver toxicity, its potential as an effective therapy has been limited. [More]
IMIM researchers identify new way of treating colorectal cancer

IMIM researchers identify new way of treating colorectal cancer

Researchers at the Institut Hospital del Mar d'Investigacions Mèdiques (IMIM) have identified a new way of treating colorectal cancer. In the study published in the journal Science Signaling, the team led by LLuís Espinosa, investigator of IMIM's research group into stem cells and cancer, have shown that inhibition of endosomal activity is a potential therapeutic strategy for the treatment of cancers with the BRAF mutated gene. [More]
Sysmex Inostics to offer OncoBEAM CLIA laboratory services in Germany, Austria and Switzerland

Sysmex Inostics to offer OncoBEAM CLIA laboratory services in Germany, Austria and Switzerland

Sysmex Inostics, a subsidiary of Sysmex Corporation, today announced that they have signed an exclusive distributor agreement with IndivuTest GmbH, and its parent company Indivumed GmbH, a cancer research company focused on the development of individualized cancer diagnostics and therapies. [More]
Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

CTI BioPharma Corp. and Baxter International Inc. today announced that data from the randomized Phase 3 PERSIST-1 trial evaluating the investigational agent pacritinib in patients with myelofibrosis will be highlighted in a late-breaking oral presentation at the upcoming American Society of Clinical Oncology 2015 Meeting (May 29-June 2, 2015 in Chicago, Ill). [More]
Advertisement
Advertisement